Effects Of Argatroban On Serum Gal-3,CTRP9 Levels And 90-Day Prognosis In Patients With Acute Ischemic Stroke

Objective:To explore the effects of argatroban on serum Galectin-3（Gal-3）,C1q/TNF-related protein 9（CTRP9）levels and 90-day prognosis in patients with acute ischemic stroke.Methods:A total of 120 AIS patients admitted to the Department of Neurology of the Affiliated Hospital of Chengde Medical College from November 2021 to July 2022 were selected as the study objects.According to the method of random number table,they were divided into treatment group（Argatroban group）and control group（non-Argatroban group）with 60 cases each.The control group was given routine treatment(According to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018^[1],the routine treatment was given aspirin 150-300mg/d or clopidogrel to prevent platelet aggregation,statins to regulate lipid and stabilize plaque,improve cerebral blood circulation,control blood pressure and blood sugar,and symptomatic treatment),and the treatment group was given intravenous injection of argatroban on the basis of routine treatment.Observe the treatment effect of the two groups of patients,and conduct outpatient and telephone follow-up 90 days after the treatment to assess their daily living ability.The levels of serum Gal-3 and CTRP9 were detected by enzyme-linked immunosorbent assay before and after treatment.Baseline data of hospitalized patients were collected,such as sex,age,blood lipids,smoking,drinking,hypertension,etc.Compare whether the baseline data of the two groups are statistically significant（The difference is statistically significant with P<0.05）.Results:1.There was no significant difference in baseline data between the two groups,such as sex,age,hypertension,diabetes,coronary heart disease,smoking history,drinking history,blood lipid,etc.（P>0.05）.2.Compared with the control group,the level of serum Gal-3 decreased significantly after 7d of treatment with argatroban（P<0.05）;The expression level of serum CTRP9 increased significantly（P<0.05）.3.Compared with the control group,the NIHSS score of Argatroban group decreased after 7d of treatment,but the difference was not statistically significant（P>0.05）.4.Compared with the control group,Argatroban group had a better prognosis（P<0.05）.Conclusions:1.Compared with the control group,argatroban is more satisfied with the improvement of long-term prognosis of AIS patients.2.Argatroban can improve endothelial cell function and regulate various cell factor that cause inflammation and thrombus.The experiment shows that argatroban may improve the neurological deficit and prognosis of patients by regulating the changes of serum Gal-3 and CTRP9 levels.